Amy Lan Chen

US Patent:

8146654, Apr 3, 2012

Filed:

Jun 18, 2007

Appl. No.:

12/306242

Inventors:

James R. Bragg - Houston TX, US
Joseph P. Lederhos - Houston TX, US
Sergio A. Leonardi - Pearland TX, US
Scott E. Hommema - Pearland TX, US
Amy L. Chen - Cypress TX, US
Shan H. Yang - Sugar Land TX, US

Assignee:

ExxonMobil Upstream Research Company - Houston TX

International Classification:

E21B 33/138
E21B 43/22
E21B 43/24
E21B 47/00
E21B 47/10

US Classification:

16625001, 166263, 166270, 1662721, 166288, 166294, 166302, 166303, 166304, 507203, 507904

Abstract:

A waxy oil-external emulsion is provided for injection into a selected zone of a subsurface formation. The selected zone is typically a high permeability zone. The emulsion generally comprises oil, added wax, and water. The emulsion may also include an emulsifying agent and a solvent. The emulsion is formulated to be a liquid at a temperature greater than a targeted temperature in the subsurface formation, but a solid at the targeted temperature. The targeted temperature is typically the maximum operating temperature for the formation. A method of formulating the emulsion is also provided. Further, a method of plugging a high permeability zone using the emulsion is disclosed.

US Patent:

20120149605, Jun 14, 2012

Filed:

Feb 21, 2012

Appl. No.:

13/401570

Inventors:

James R. Bragg - Houston TX, US
Joseph P. Lederhos - Houston TX, US
Sergio A. Leonardi - Pearland TX, US
Scott E. Hommema - Pearland TX, US
Amy L. Chen - Cypress TX, US
Shan H. Yang - Houston TX, US

International Classification:

C09K 8/86

US Classification:

507203

Abstract:

A waxy oil-external emulsion is provided for injection into a selected zone of a subsurface formation. The selected zone is typically a high permeability zone. The emulsion generally comprises oil, added wax, and water. The emulsion may also include an emulsifying agent and a solvent. The emulsion is formulated to be a liquid at a temperature greater than a targeted temperature in the subsurface formation, but a solid at the targeted temperature. The targeted temperature is typically the maximum operating temperature for the formation. A method of formulating the emulsion is also provided. Further, a method of plugging a high permeability zone using the emulsion is disclosed.

US Patent:

20220196651, Jun 23, 2022

Filed:

Dec 6, 2021

Appl. No.:

17/543569

Inventors:

- South San Francisco CA, US
Bang Janet SIM - South San Francisco CA, US
Amy Shaw-Ru CHEN - San Jose CA, US
Emma Ruth SANGALANG - Oakland CA, US

International Classification:

G01N 33/543
G01N 33/80
G01N 33/566
C07K 14/705
C07K 16/28

Abstract:

Provided are methods of reducing and/or preventing interference by a drug comprising (i) an antibody Fc region and (ii) a moiety that binds to human CD47 in serological assays.

US Patent:

20210054087, Feb 25, 2021

Filed:

Aug 27, 2020

Appl. No.:

17/005073

Inventors:

- NEW YORK NY, US
Javier Fernando CHAPARRO RIGGERS - San Mateo CA, US
Wei CHEN - Cupertino CA, US
Amy Shaw-Ru CHEN - San Jose CA, US
Edward Derrick PASCUA - Oakland CA, US
Thomas John VAN BLARCOM - Oakland CA, US
Leila Marie BOUSTANY - Redwood City CA, US
Weihsien HO - Belmont CA, US
Yik Andy YEUNG - South San Francisco CA, US
Pavel STROP - San Mateo CA, US
Arvind RAJPAL - San Francisco CA, US

Assignee:

PFIZER INC. - NEW YORK NY

International Classification:

C07K 16/28
A61K 39/395
A61K 31/454
A61K 31/704
A61K 31/69
A61K 47/68

Abstract:

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

US Patent:

20180298108, Oct 18, 2018

Filed:

Jun 25, 2018

Appl. No.:

16/017974

Inventors:

- NEW YORK NY, US
Javier Fernando CHAPARRO RIGGERS - San Mateo CA, US
Wei CHEN - Cupertino CA, US
Amy Shaw-Ru CHEN - San Jose CA, US
Edward Derrick PASCUA - Oakland CA, US
Thomas John VAN BLARCOM - Oakland CA, US
Leila Marie BOUSTANY - Redwood City CA, US
Weihsien HO - Belmont CA, US
Yik Andy YEUNG - South San Francisco CA, US
Pavel STROP - San Mateo CA, US
Arvind RAJPAL - San Francisco CA, US

Assignee:

PFIZER INC. - NEW YORK NY

International Classification:

C07K 16/28
A61K 39/395
A61K 31/704
A61K 31/454
A61K 47/68

Abstract:

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

US Patent:

20180171018, Jun 21, 2018

Filed:

Jan 23, 2018

Appl. No.:

15/878344

Inventors:

- NEW YORK NY, US
Javier Fernando CHAPARRO RIGGERS - San Mateo CA, US
Wei CHEN - Cupertino CA, US
Amy Shaw-Ru CHEN - San Jose CA, US
Edward Derrick PASCUA - Oakland CA, US
Thomas John VAN BLARCOM - Oakland CA, US
Leila Marie BOUSTANY - Redwood City CA, US
Weihsien HO - Belmont CA, US
Yik Andy YEUNG - South San Francisco CA, US
Pavel STROP - San Mateo CA, US
Arvind RAJPAL - San Francisco CA, US

Assignee:

PFIZER INC. - NEW YORK NY

International Classification:

C07K 16/28
A61K 39/395
A61K 47/68
A61K 31/454
A61K 31/69
A61K 31/704
A61K 39/00

Abstract:

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

US Patent:

20160297885, Oct 13, 2016

Filed:

Mar 30, 2016

Appl. No.:

15/085644

Inventors:

- NEW YORK NY, US
Javier Fernando CHAPARRO RIGGERS - San Mateo CA, US
Wei CHEN - Cupertino CA, US
Amy Shaw-Ru CHEN - San Jose CA, US
Edward Derrick PASCUA - Oakland CA, US
Thomas John VAN BLARCOM - Oakland CA, US
Leila Marie BOUSTANY - Redwood City CA, US
Weihsien HO - Belmont CA, US
Yik Andy YEUNG - South San Francisco CA, US
Pavel STROP - San Mateo CA, US
Arvind RAJPAL - San Francisco CA, US

Assignee:

PFIZER INC. - NEW YORK NY

International Classification:

C07K 16/28
A61K 31/704
A61K 38/07
A61K 38/05
A61K 39/395
A61K 31/454

Abstract:

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.